3D Printing Muscles

By on March 2nd, 2012 in Corporate


Organovo, the 3D Bioprinting startup, announced they’ve received USD$6.5M in a private placement investment to bolster their research budget. 
Organovo has been working on the problem of 3D printing live human tissue – but not with the intention of surgically inserting said tissue into live humans. No, instead they wish to create live human tissue in such a way to permit drug and therapy testing without involving human or animal subjects. According to Keith Murphy, Organovo CEO: 
Organovo’s advanced bioprinting platform can replicate essential biology for research, drug discovery and development and, eventually, for therapeutic applications. We have found success in achieving early revenue through strategic collaborations, and this funding will allow us to extend the reach and uses of 3D bioprinting through growth and innovation in the coming years.

By Kerry Stevenson

Kerry Stevenson, aka "General Fabb" has written over 8,000 stories on 3D printing at Fabbaloo since he launched the venture in 2007, with an intention to promote and grow the incredible technology of 3D printing across the world. So far, it seems to be working!